VP and General Manager, Global Proteomics Solutions at Illumina

San Diego, California, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Healthcare, Life SciencesIndustries

Requirements

Reporting to the SVP and Business Leader for Illumina’s emerging growth businesses
Visionary leadership to expand Illumina’s footprint in the proteomics market
Bold business builder to run all aspects of the Global Proteomics Solutions business
Oversee a global fully cross-functional team including research and technology development, product development, product management, marketing, and global/regional commercial teams
Deep understanding of market trends
Commitment to creativity
Lead the integration of a recently announced acquisition
Work closely with internal teams, Executive Leadership Team, and CEO

Responsibilities

Oversee a global fully cross-functional team for the Global Proteomics Solutions business
Provide visionary leadership to expand Illumina’s position in the large proteomics application space
Deliver a complete portfolio of proteomics solutions, including consumables, software, and proteomic services across research and clinical customers
Expand the adoption of NGS and micro-array based technologies into the proteomics market, focusing on high plexity, high throughput proteomics at scale via simple, automated workflows and end-to-end solutions including bioinformatics and services
Manage all aspects of the business enterprise-wide and end-to-end
Strive to serve the interests and mission of Illumina

Skills

Proteomics

Genomics

NGS

DNA Sequencing

Business Leadership

P&L Management

Strategic Planning

Illumina

Supports genomics startups through funding and resources

About Illumina

Illumina focuses on fostering innovation in the genomics industry by supporting startups through its Illumina Accelerator program. This program helps entrepreneurs create, launch, and grow genomics-focused companies by providing funding and resources. The accelerator operates in two main locations: the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator has successfully invested in 68 genomics startups, which have collectively raised over $1 billion in venture capital. What sets Illumina apart from its competitors is its strong partnership with leading venture capital investors and its dedicated focus on the genomics sector. The goal of Illumina is to build a thriving ecosystem for genomics innovation, enabling new companies to emerge and advance the field.

San Diego, CaliforniaHeadquarters

1998Year Founded

$27.2MTotal Funding

IPOCompany Stage

Venture Capital, BiotechnologyIndustries

5,001-10,000Employees

Risks

Over-reliance on NVIDIA's AI technology may limit flexibility in AI solution adoption.

Standardizing proteomics data across platforms could challenge Illumina's data reliability.

Single-flow-cell NovaSeq X System might cannibalize sales of higher-end models.

Differentiation

Illumina leads in genomic sequencing with advanced AI integration and multiomic data analysis.

The company offers innovative array-based solutions for DNA, RNA, and protein analysis.

Illumina's global expansion includes a new Global Capability Center in Bengaluru.

Upsides

Collaboration with NVIDIA enhances drug discovery and clinical development through AI integration.

Pilot proteomics program with UK Biobank aims to generate crucial reference datasets.

Single-cell sequencing kits make high-throughput sequencing accessible to smaller labs.

Land your dream remote job 3x faster with AI

Try Jobo Free